Federal award (DELIVERY ORDER, fiscal year 2022)
Recipient: WESTAT, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2023-06-01 to 2027-05-31
Current total value of award: $2220803
Description: PHASE I/II DOSE-FINDING, SAFETY, AND TOLERABILITY STUDY OF DAILY RIFAPENTINE (RPT) COMBINED WITH ISONIAZID (INH) (1HP) FOR TUBERCULOSIS PREVENTION IN CHILDREN TWO TO LESS THAN 13 YEARS OF AGE WITH AND WITHOUT HIV